June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Active-type Vitamin D3 Attenuates Fulguration-induced Meibomian Gland Dysfunction of Mice
Author Affiliations & Notes
  • Kai Jin
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Footnotes
    Commercial Relationships Kai Jin, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 307. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kai Jin; Active-type Vitamin D3 Attenuates Fulguration-induced Meibomian Gland Dysfunction of Mice. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):307.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To investigate the efficacy and safety of active-type vitamin D treatment of meibomian gland dysfunction (MGD) in mice

Methods: Meibomian gland orifices of the upper eyelid were fulgurated slightly to create a meibomian gland dysfunction model using male C57BL/6JJcl mice (N=40). Fulguration-induced MGD mice were randomly divided into two groups: maxacalcitol (22-oxacalcitriol, an analog of active vitamin D) group and Vaseline group. Non-fulgurated left eyelids were used as normal control. Maxacalcitol or Vaseline ointment were applied on the upper lid margin 5 days a week for 2 months. Maxacalcitol or Vaseline ointment were also applied on the normal lid margin to evaluate their safety. Changes in the tarsus surface, conjunctiva, cornea and eyelid margin were observed by microscopy. Morphological changes of meibomian gland were examined by meibography of transparentized eyelids. Pathological alteration of meibomian gland were investigated by haemotoxylin and eosin (HE) staining and oil-red o staining.

Results: The atrophy of the meibomian glands can be alleviated by maxacalcitol application compared to Vaseline or normal control, especially during the first 2 weeks. After 2 weeks, statistically significant alleviation were shown by meibography of those eyelids (p<0.05). The cornea was not affected by maxacalcitol application during our 2-month observation.

Conclusions: Maxacalcitol, active-type vitamin D3 possesses the ability to attenuate fulguration-induced MGD and is a potential safe adjuvant of MGD treatment.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.